Insmed initiates three Phase 3 TPIP studies

• Insmed (NASDAQ:INSM) initiated three Phase 3 clinical trials for its once-daily TPIP inhalation powder within the global PALM program.
• The company aims to enroll more than 2,000 patients across four distinct pulmonary disease indications.
• The PALM development program supports the strategic advancement of investigational TPIP toward potential regulatory approvals.

Insmed (NASDAQ:INSM) initiated three Phase 3 studies in its PALM program, targeting total enrollment of over 2,000 patients.

The program evaluates once-daily treprostinil palmitil inhalation powder across four distinct pulmonary disease indications.

Insmed started the PALM-PAH, PALM-ILD, and PALM-PPF trials, with the PALM-IPF study planned for the first half of 2027.

The studies measure six-minute walking distance changes at Week 24 and forced vital capacity at Week 52.

Treatment durations for the progressive pulmonary fibrosis and planned idiopathic pulmonary fibrosis trials range from 52 to 104 weeks.

Insmed plans to feature the program at CHEST 2026, while treprostinil palmitil inhalation powder remains investigational and unapproved globally.